LETTERS

Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort

Data on the efficacy of drugs for preventing multiple drug resistant tuberculosis (MDR-TB) in people at risk after close contact with patients is lacking. In a systematic review, we found only two small cohort studies that addressed this question.¹ The aim of the present study was to describe the incidence of MDR-TB disease in people who were in close contact with patients with pulmonary MDR-TB, and to compare the incidence in people that were offered prophylaxis to those that were not (see online appendix).

Patients with MDR-TB were identified by inspecting the records of patients that were referred to the nine designated TB centres in Israel; records of the national referral laboratory and the central registry held by the Ministry of Health from 1998 to the end of 2006. Patients with MDR-TB diagnosed from 1998 to 2003 were defined as cases (patients). For each patient, we extracted demographic and clinical data, and data on close contacts. For each contact, demographic and clinical data, and whether they were advised to take prophylaxis, were recorded. Israel has no guidelines for prophylaxis in close contacts of patients with MDR-TB, and the decision is at the discretion of the treating physician.

The list of close contacts was matched to the list of MDR-TB patients (years 1998–2006) according to the Israeli national ID number, and by family name. Follow-up for contacts was defined as the interval from the initial interview to the end of 2006. The study was approved by the research ethics committee of Rabin Medical Centre.

During 1998–2003, 78 patients with pulmonary MDR-TB were newly diagnosed in

Israel (table 1). A total number of 476 close contacts were identified (mean of 6 contacts per patients, median 4, range 1–47; median age of contacts 29 years, range 2–87). The median values of their tuberculin skin reaction was 10 mm (range 0–36) and 245 had a skin reaction ≥ 10 mm. Median follow-up for contacts was 6 years (range 3–8), a total of 2666 person-years. Twelve contacts were offered treatment with a tailored regimen (mainly ciprofloxacin and pyrazinamide), all of them with a positive tuberculin skin reaction; 71 were given isoniazid, six other treatments and 387 were not offered treatment.

No cases of MDR-TB were detected in the contacts during the follow-up period (0% of 476 patients, 95% confidence interval (CI) 0.0% to 0.7%; in incidence density terms, 0 cases during 2666 person years, 95% CI 0.0 to 1.0 cases per 1000 person years).

These low values are compatible with the observation that resistant strains are less likely to result in secondary cases.² However, the data were obtained in a location with an overall low prevalence and incidence of TB, and where an effective (and resource consuming) national programme for detection of patients and contacts, directly observed treatment, follow-up and isolation of culture positive patients is in place. In locations with a high prevalence of TB and no such programme, rates as high as 8% were described in contacts of MDR-TB patients.³

Regimens recommended for treating latent TB in contacts of MDR-TB patients are associated with toxicity.⁴ Our results support a policy of no treatment, close observation of MDR-TB close contacts in settings similar to the one we describe.

A Attamna,¹ D Chemtob,² S Attamna,¹ A Fraser,³ E Rorman,⁴ M Paul,^{3,5} L Leibovici^{3,5}

¹ Hasharon Regional Tuberculosis Clinic, Clalit Health Services, Hadera, Israel; ² Department of Tuberculosis and AIDS, Ministry of Health, Jerusalem, Israel; ³ Department of Medicine E, Rabin Medical Centre, Beilinson Campus, Petah-Tiqva, Israel; ⁴ National Public Health Laboratory, Ministry of Health, Tel-Aviv, Israel; ⁵ Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Correspondence to: Professor L Leibovici, Department of Medicine E, Beilinson Campus, Rabin Medical Centre, Petah-Tiqva 49100, Israel; leibovic@post.tau.ac.il

Funding: The study was funded in part by a grant from the Bequest Fund, Israel; and a grant from the Israeli League for Prevention of Pulmonary Diseases. The sponsors had no part in designing the study, performing it or analysing the data.

Competing interests: None.

Ethics approval: The study was approved by the research ethics committee of Rabin Medical Centre.

► An appendix is published online only at <http://thorax.bmj.com/content/vol64/issue3>

Accepted 24 August 2008

Thorax 2009;64:271. doi:10.1136/thx.2008.100974

REFERENCES

1. Fraser A, Paul M, Attamna A, *et al.* Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. *Int J Tuberc Lung Dis* 2005;10:19–23.

2. Burgos M, DeRiemer K, Small PM, *et al.* Effect of drug resistance on the generation of secondary cases of tuberculosis. *J Infect Dis* 2003;188:1878–84.
3. Kritski AL, Marques MJ, Rabahi MF, *et al.* Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. *Am J Respir Crit Care Med* 1996;153:331–5.
4. Papastavros T, Dolovich LR, Holbrook A, *et al.* Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. *CMAJ* 2002;167:131–6.

Aminoglycoside ototoxicity susceptibility in cystic fibrosis

Ototoxicity is a recognised dose-related complication of aminoglycoside antibiotics.

Predisposition to these ototoxic effects, even when levels are within the therapeutic range, is associated with an inherited mitochondrial DNA mutation known as m.1555A>G.^{1,2}

We report a case of a 22-year-old woman with cystic fibrosis (CF), genotype delta F508 homozygous, with bilateral high frequency hearing loss. This was discovered when an audiogram (not previously performed) was requested for routine screening by our centre before commencement of nebulised TOBI (preservative-free pH-adjusted preparation of tobramycin for inhalation).

She had a history of diabetes mellitus, exocrine pancreatic insufficiency and developed chronic *Pseudomonas aeruginosa* infection when aged 5 years. She had received regular intravenous antibiotics at both paediatric and adult CF centres, which usually included a β -lactam and an aminoglycoside. Since transfer to the adult centre at the age of 18, she had received an average of three courses of antibiotics per year, predominantly tobramycin and ceftazidime. There were no risk factors for noise-induced hearing loss. Current medication included oral azithromycin, nebulised dornase alfa and TOBI.

Although the patient did not complain of hearing loss, the audiogram showed that the hearing threshold was reduced 3–8 kHz (fig 1) with normal middle ear pressures. This is consistent with hearing loss associated with aminoglycoside toxicity.

As a consequence of this result, she underwent DNA testing for the deafness mutation m.1555A>G and was found to be positive heteroplasmic (intermediate 30–70%). There is no family history of hearing impairment although, as far as we are aware, her relatives have not received intravenous aminoglycosides. The genetic report did comment that her surname was known and that she may belong to a family known to have m.1555A>G.

We now plan to avoid intravenous aminoglycosides in this patient and perform surveillance audiograms while she continues on nebulised TOBI.

To our knowledge, this is the first report of a patient with CF with this mitochondrial

Table 1 Characteristics of 78 patients with MDR-TB

Characteristic	
Women	25 (32)
Age (years)	39 (15–93)
Place of birth	
Former USSR	58 (74)
Ethiopia	9 (12)
Israel	2 (3)
Other	9 (12)
Years since emigrated to Israel	3.5 (0–65)
TB in the past*	36 (46)
Treated for TB in the past*	27 (35)
IV drug abuse	9 (12)
HIV positive	6 (8)
No of contacts	4 (1–47)

Categorical values are given as number (%) and continuous data as median (range).

MDR-TB, multiple drug resistant tuberculosis.

Figure 1 Audiogram showing bilateral high frequency hearing loss.

mutation. The prevalence of the m.1555A>G mutation in the UK is quoted as 1 in 40 000, but this figure is based on studies in children who are born deaf. Variable gene penetrance and aminoglycoside exposure means the actual prevalence is likely to be higher.³

The use of aminoglycoside antibiotics is widespread in CF care. First isolation of *P aeruginosa* in a patient with CF necessitates treatment to eradicate it. Nebulised and oral antibiotics or intravenous antibiotics are used.⁴ For chronic *P aeruginosa* infection, intermittent intravenous antibiotics are frequently required. To prevent antibiotic resistance, two agents are used—usually a β -lactam and an aminoglycoside.⁵ Ototoxicity and renal toxicity with aminoglycosides are well recognised, but these factors need to be balanced against clinical need.

The cost-effectiveness of screening for the m.1555A>G mutation in individuals who will potentially receive aminoglycosides makes financial sense, given the costs to the health service and to society of meeting the needs of profoundly deaf individuals.³ This case highlights the potential need for more widespread screening for the m.1555A>G mutation in patients with CF. This will ensure that we can protect against aminoglycoside ototoxicity where possible, or at least fully inform our patients of the potential risk of deafness with these antibiotics.

S A Mulrennan, J Helm, R Bright Thomas, M Dodd, A Jones, K Webb

Adult Cystic Fibrosis Unit, Wythenshawe Hospital, Manchester, UK

Correspondence to: Professor K Webb, Adult Cystic Fibrosis Unit, Wythenshawe Hospital, Manchester M23 9LT, UK; the5webbs@hotmail.com

Competing interests: None.

Patient consent: Obtained.

Accepted 23 September 2008

Thorax 2009;64:271–272. doi:10.1136/thx.2008.103010

REFERENCES

1. Usami S, Abe S, Shinkawa H, *et al*. Sensorineural hearing loss caused by mitochondrial DNA mutations: special reference to the A1555G mutation. *J Commun Disord* 1998;**31**:423–34.
2. Hu DN, Qui WQ, Wu BT, *et al*. Genetic aspects of antibiotic induced deafness: mitochondrial inheritance. *J Med Genet* 1991;**28**:79–83.
3. Bitner-Glindzicz M, Rahman S. Ototoxicity caused by aminoglycosides. *BMJ* 2007;**335**:784–5.
4. Frederiksen B, Koch C, Højby N. Antibiotic treatment of initial colonization with *Pseudomonas aeruginosa* postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. *Pediatr Pulmonol* 1997;**23**:330–5.
5. Cheng K, Smyth RL, Govan JR, *et al*. Spread of beta-lactam-resistant *Pseudomonas aeruginosa* in a cystic fibrosis clinic. *Lancet* 1996;**348**:639–42.

Anti-IgE in Churg–Strauss syndrome

The cases reported by Grohé *et al* are interesting, but they need to be better debated.¹ As far as we know, we were the first group to administer anti-IgE to a patient with Churg–Strauss syndrome (CSS) with asthma.^{2,3}

In our patient, CSS had shown remission with systemic corticosteroid but he still presented with asthma which was difficult to control. The asthma did not improve despite the use of high-dose inhaled corticosteroids, long-acting β_2 agonists and several courses of steroid pulse therapy. Omalizumab was given and his asthma was controlled as well as could be expected, but a marked improvement in eosinophilia was also observed. The patient was not taking systemic corticosteroids or immunosuppressive agents at this time.

Besides the IgE blockage effect, studies have shown antiallergic and anti-inflammatory properties of anti-IgE, among which is the reduction in circulating and tissue eosinophils.⁴ On the other hand, there are at least three cases of temporal association between anti-IgE use and the development

of CSS.⁵ CSS was probably caused by systemic steroid tapering in these cases, rather than anti-IgE use.

In the report by Grohé *et al*, it was not clear if the patients showed only improvement in respiratory symptoms or also in other CSS manifestations after introduction of anti-IgE. Moreover, at the time omalizumab was administered, the patients were also taking corticosteroids and immunosuppressives (all these drugs were acting).

Together, these cases suggest that omalizumab can be used in patients with CSS to treat and control asthma, but they also show that anti-IgE alone is not enough to control CSS activity. Systemic corticosteroids are the drug of choice to treat this disease.⁵

Although we are getting more evidence about the safety of omalizumab in patients with asthma and CSS, larger long-term studies are needed before the widespread use of anti-IgE can be recommended and also to verify if it is effective in the treatment of CSS.

P Giavina-Bianchi, M Giavina-Bianchi, R C Agondi, J Kalil

Department of Clinical Immunology and Allergy, São Paulo University, Brazil

Correspondence to: Dr P Giavina-Bianchi, Department of Clinical Immunology and Allergy, São Paulo University, Brazil; saudesos@saudesos.com.br

Competing interests: None.

Accepted 8 October 2008

REFERENCES

1. Grohé C, Tiyerili V, Pabst S. Apparent response to anti-IgE therapy in two patients with refractory “forme fruste” of Churg Strauss syndrome. *Thorax* 2008;**63**:747–8.
2. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, *et al*. Administration of anti-IgE to a patient with Churg–Strauss syndrome. *Int Arch Allergy Immunol* 2007;**144**:155–8.
3. Giavina-Bianchi P, Agondi R, Kalil J. One year administration of anti-IgE to a patient with Churg–Strauss syndrome. *Int Arch Allergy Immunol* 2008;**146**:176.
4. Noga O, Hanf G, Brachmann I, *et al*. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. *J Allergy Clin Immunol* 2006;**117**:1493–9.
5. Giavina-Bianchi P, Giavina-Bianchi M, *et al*. Omalizumab and Churg–Strauss syndrome. *J Allergy Clin Immunol* 2008;**122**:217.

Authors' reply

We thank Giavina-Bianchi *et al* for their response to our letter. Treatment of patients with Churg–Strauss syndrome (CSS) remains a challenge owing to the heterogeneity of the underlying symptoms. We have followed our patients since early 2006 and have noticed an overall improvement in both pulmonary (obstructive airway disease) and systemic (ie, congestive) heart failure as a result of the addition of omalizumab. In particular, compared with the prior worsening, the clinical course of both patients